ValiRx selected for The Parliamentary Review 2016

RNS Number : 7460K

ValiRx PLC

26 September 2016

 

VALIRX PLC

                    ("ValiRx", "the Company" or "the Group")

ValiRx has been selected to appear in the 2015/16 edition of

The Parliamentary Review

"The Company features alongside The Chancellor of the Exchequer, The Rt Hon Philip Hammond, and a small number of outstanding organisations in the Technology edition"

London, UK., 26 September 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, is pleased to report that it has been selected to appear in the 2015/16 edition of The Parliamentary Review.

Established by former minister The Rt Hon David Curry shortly after the 2010 general election, The Parliamentary Review's September release has become a key fixture in the political calendar.

ValiRx features alongside The Chancellor of the Exchequer, The Rt Hon Philip Hammond, and a small number of outstanding organisations in the Technology edition. The main aim of The Review is to showcase best practice as a learning tool to the public and private sector, with this edition aimed particularly at leading policymakers and executives within Technology.

Alongside pieces from the selected representatives and an introduction from the Chancellor, it contains a look back at the year in Westminster and Technology, with the political commentary written by Mark D'Arcy (BBC's Parliamentary Correspondent).

The document is sent out to tens of thousands of leading policymakers. The articles in The Review act as both a blueprint for success and a template for reform.

Director of The Parliamentary Review, Daniel Yossman, said: "It's been an utter privilege to work with a range of organisations from across the country in this year's Review. Without their input, our aims of spreading expert knowledge and raising standards simply would not be achievable. They'll be a hard act to follow and next year's organisations will have to be on the top of their game to meet the challenge."

Editor of The Parliamentary Review, The Rt Hon David Curry, said: "Each of the representatives brings something very different to the table, while at the same time capitalising on the collective wisdom of their industry. There may be choppy waters ahead but organisations across the country would be well-advised to keep an eye on the representatives in this year's Review when deciding how to set their sails."

Chancellor of the Exchequer, The Rt Hon Philip Hammond, concurred: "The message we take to the world is this: we are the same outward-looking, globally-minded, big-thinking country we have always been - and we remain very firmly open for business."

Dr Satu Vainikka, Chief Executive of ValiRx, commented:

"We at ValiRx are thrilled to have been chosen to feature in this year's review alongside such an august and select group of companies.  Our inclusion is a very welcome endorsement of the Company and of its earnest ambition to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention".

An e-copy of The 2016 Parliamentary Review and the technology edition can be viewed via the following link:

http://www.theparliamentaryreview.co.uk/editions/pdfs/TPR2016-Technology.pdf

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]

Notes for Editors

ValiRx Plc

ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

END

 

 

NRAEAKNDADEKEFF